Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Phase 3 DUO-E/GOG-3041/ENGOT-EN10 Trial - Durvalumab + Carboplatin/Paclitaxel Followed by Maintenance Durvalumab±Olaparib for Newly Diagnosed Advanced/Recurrent Endometrial Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shannon Westin
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shannon Westin
Login to view comments.
Click here to Login
Gynecologic